[Buflomedil and nicergoline in the targeted treatment of acute cerebral ischemia. Randomized comparative double blind study].
Acute cerebral ischaemia may take considerable advantages of an adequate intensive therapy associated with a specific treatment of cerebral oedemas, especially in terms of mortality-rate reduction. Moreover, target treatment of acute cerebral ischaemia may produce excellent results in severe cases selected by means of EEG-chronospectrography. Double-blind, randomized comparison between nicergolin and buflomedil especialls showed that the latter reduces mortality three times as much as nicergolin, and leads to a 200% increment in the complete recovery of the "functio laesa", limited to those cases, which showed an appreciable improvement following EEG-chronospectrographical survey.
D000208:Acute Disease; D000368:Aged; D002545:Brain Ischemia / Q000188:drug therapy*; D002560:Cerebrovascular Circulation; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004569:Electroencephalography; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009530:Nicergoline / Q000494:pharmacology / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation
D004873:Ergolines; D011759:Pyrrolidines; D009530:Nicergoline; C010651:buflomedil
Buflomedil e Nicergolina nel trattamento mirato dell'ischemia cerebrale acuta. Confronto randomizzato in doppio cieco.